- Home
- TNXP vs GOVX Comparison
TNXP vs GOVX Comparison
Compare TNXP & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- GOVX
- Stock Information
- Founded
- TNXP 2007
- GOVX 2001
- Country
- TNXP United States
- GOVX United States
- Employees
- TNXP N/A
- GOVX N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- GOVX Health Care
- Exchange
- TNXP Nasdaq
- GOVX Nasdaq
- Market Cap
- TNXP 19.5M
- GOVX 17.1M
- IPO Year
- TNXP N/A
- GOVX N/A
- Fundamental
- Price
- TNXP $0.20
- GOVX $2.71
- Analyst Decision
- TNXP Strong Buy
- GOVX Strong Buy
- Analyst Count
- TNXP 2
- GOVX 5
- Target Price
- TNXP $53.50
- GOVX $14.20
- AVG Volume (30 Days)
- TNXP 51.5M
- GOVX 3.5M
- Earning Date
- TNXP 11-12-2024
- GOVX 11-12-2024
- Dividend Yield
- TNXP N/A
- GOVX N/A
- EPS Growth
- TNXP N/A
- GOVX N/A
- EPS
- TNXP N/A
- GOVX N/A
- Revenue
- TNXP $11,291,000.00
- GOVX $3,090,161.00
- Revenue This Year
- TNXP $62.53
- GOVX N/A
- Revenue Next Year
- TNXP $26.17
- GOVX $565.58
- P/E Ratio
- TNXP N/A
- GOVX N/A
- Revenue Growth
- TNXP 183.05
- GOVX N/A
- 52 Week Low
- TNXP $0.12
- GOVX $1.09
- 52 Week High
- TNXP $22.08
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- TNXP 66.43
- GOVX 54.52
- Support Level
- TNXP $0.17
- GOVX $2.53
- Resistance Level
- TNXP $0.28
- GOVX $3.12
- Average True Range (ATR)
- TNXP 0.02
- GOVX 0.39
- MACD
- TNXP 0.01
- GOVX 0.07
- Stochastic Oscillator
- TNXP 44.53
- GOVX 44.60
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.